Who Paid My Doc
Dtx401-Cl301
Research payments
$4,424,180
Through program year 2025, $4,424,180 in research payments was reported against Dtx401-Cl301, across 276 payments, paid by Ultragenyx Pharmaceutical Inc..
- Paid by
- Ultragenyx Pharmaceutical Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $1,584,997 | 113 |
| 2023 | Research | $2,069,619 | 95 |
| 2022 | Research | $636,001 | 63 |
| 2021 | Research | $133,562 | 5 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Diva Deleon Philadelphia, PA Named on 89 payments
- Rebecca Riba-Wolman Hartford, CT Named on 31 payments
- Areeg El-Gharbawy Durham, NC Named on 23 payments
- Jose Abdenur Orange, CA Named on 22 payments
- Brian Shayota Salt Lake City, UT Named on 14 payments
- Ayesha Ahmad Ann Arbor, MI Named on 13 payments
- Nicola Longo Salt Lake City, UT Named on 9 payments
- David Rodriguez Houston, TX Named on 8 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.